PT  - JOURNAL ARTICLE
AU  - Matveyenko, Aleksey V.
AU  - Dry, Sarah
AU  - Cox, Heather I.
AU  - Moshtaghian, Artemis
AU  - Gurlo, Tatyana
AU  - Galasso, Ryan
AU  - Butler, Alexandra E.
AU  - Butler, Peter C.
TI  - Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes
AID  - 10.2337/db09-0058
DP  - 2009 Jul 01
TA  - Diabetes
PG  - 1604--1615
VI  - 58
IP  - 7
4099  - http://diabetes.diabetesjournals.org/content/58/7/1604.short
4100  - http://diabetes.diabetesjournals.org/content/58/7/1604.full
SO  - Diabetes2009 Jul 01; 58
AB  - OBJECTIVE We sought to establish the extent and mechanisms by which sitagliptin and metformin singly and in combination modify islet disease progression in human islet amyloid polypeptide transgenic (HIP) rats, a model for type 2 diabetes. RESEARCH DESIGN AND METHODS HIP rats were treated with sitagliptin, metformin, sitagliptin plus metformin, or no drug as controls for 12 weeks. Fasting blood glucose, insulin sensitivity, and β-cell mass, function, and turnover were measured in each group. RESULTS Sitagliptin plus metformin had synergistic effects to preserve β-cell mass in HIP rats. Metformin more than sitagliptin inhibited β-cell apoptosis. Metformin enhanced hepatic insulin sensitivity; sitagliptin enhanced extrahepatic insulin sensitivity with a synergistic effect in combination. β-Cell function was partially preserved by sitagliptin plus metformin. However, sitagliptin treatment was associated with increased pancreatic ductal turnover, ductal metaplasia, and, in one rat, pancreatitis. CONCLUSIONS The combination of metformin and sitagliptin had synergistic actions to preserve β-cell mass and function and enhance insulin sensitivity in the HIP rat model of type 2 diabetes. However, adverse actions of sitagliptin treatment on exocrine pancreas raise concerns that require further evaluation.